new indications for glp-1 drugs Obesity Imaging & The Era of GLP‑1 Trials Oral semaglutide (Rybelsus) is the

The increasing prevalence of obesity worldwide and its associated pressure on healthcare systems, along with the reputation of GLP-1 drugs for inducing significant weight loss (approximately 1525+%, significantly higher than previous generations of obesity drugs), are driving GLP-1 drug expansion into new markets like China

Incubation with 1 M L3740 for 48 h has increased GLP-1 secretion and the number of L-cells in human and mouse intestinal organoids through GLP-1R signaling and serotonin signaling

Obesity is a chronic condition that needs long-term management

This foundational discovery later recognized with the 2024 LaskerDeBakey Clinical Medical Research Award for Habener, Mojsov, and Lotte Bjerre Knudsen laid the foundation for an entirely new class of GLP-1 medications.[1] Gut releases natural GLP-1 that is destroyed in the bloodstream within about two minutes by the enzyme DPP-4 that is a widely distributed integral membrane protein that is expressed in the intestine, kidney, vascular endothelium, liver pancreas, glandular epithelial cells, and immune system cells.[17] Hence, DPP-4 inhibitors are a successful class of anti-hyperglycaemic agents used to treat type 2 diabetes (T2DM) via protecting GLP-1

nAMD Symptoms May Include: Distortion of straight lines (metamorphopsia) Blurred or fuzzy central vision Dark or empty areas in the center of vision Difficulty seeing fine detail, even with glasses Sudden worsening of visual acuity The aggressive nature of nAMD means early detection plays a key role in preventing permanent vision loss

The primary endpoints were changes in patient-reported quality of life using the KCCQ clinical summary score and changes in body weight